EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Optimising protamine dosing for heparin reversal after cardiopulmonary bypass: a population pharmacokinetic–pharmacodynamic study

Julien Lanoiselée, Audrick Gibert, Isabelle Gouin-Thibault, Alexandre Mansour, Adeline Pontis, Camille Morizot, Marie Goset, Serge Molliex, Jérôme Morel, Pauline Noyel, Kasra Azarnoush, Andranik Petrosyan und 3 weitere

British Journal of Anaesthesia · 2026

DOI: 10.1016/j.bja.2025.11.057 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift British Journal of Anaesthesia, 2026. Verfasst von Julien Lanoiselée und 14 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Health and Medical Research, U1059, Vascular Dysfunction and Hemostasis, Saint-Étienne, France; Department of Anesthesia and In…. Hauptthemen laut MEDLINE: Anticoagulants, Cardiopulmonary Bypass, Heparin, Heparin Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Société Française d’Anesthésie et de Réanimation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Protamine is administered to reverse unfractionated heparin (UFH) after cardiopulmonary bypass (CPB), but dosing strategies-typically based on protamine-to-heparin (P:H) ratios-vary, and the minimal effective dose remains unclear. Reversal is commonly assessed using activated clotting time (ACT), which may not reliably reflect residual heparin activity. We used pharmacometric modeling to determine a minimal effective P:H ratio and to characterise the anti-factor Xa (anti-Xa) activity-ACT relationship. METHODS: In this prospective, single-centre study, 68 adults undergoing CPB-assisted cardiac surgery were enrolled. A total of 757 blood samples were collected intraoperatively and after UFH reversal to measure anti-Xa activity and ACT. A population pharmacokinetic-pharmacodynamic model was developed using a nonlinear mixed-effects approach to describe UFH neutralisation by protamine. This model was then used to perform Monte Carlo simulations estimating the probability of complete reversal (anti-Xa

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsCardiopulmonary BypassHeparinHeparin AntagonistsProtaminesAdultAgedFemaleHumansMaleMiddle AgedDose-Response Relationship, DrugModels, BiologicalMonte Carlo MethodProspective Studies

Stichwörter der Autor:innen

Monte Carlo simulationanticoagulation reversalcardiopulmonary bypassheparinnonlinear mixed-effects modelingpharmacokineticsprotamine

Substanzen

AnticoagulantsHeparinHeparin AntagonistsProtamines

Autor:innen und Institutionen

  • National Institute of Health and Medical Research, U1059, Vascular Dysfunction and Hemostasis, Saint-Étienne, France; Department of Anesthesia and Intensive Care, University Hospital of Saint-Étienne, Saint-Étienne, Fra…
  • National Institute of Health and Medical Research, U1059, Vascular Dysfunction and Hemostasis, Saint-Étienne, France.
  • Department of Hematology, Pontchaillou, University Hospital of Rennes, Rennes, France; University of Rennes, National Institute of Health and Medical Research, Research Institute for Environmental and Occupational Healt…
  • University of Rennes, National Institute of Health and Medical Research, Research Institute for Environmental and Occupational Health, Rennes, France; Department of Anesthesia and Critical Care, Pontchaillou, University…
  • Department of Anesthesia and Intensive Care, University Hospital of Saint-Étienne, Saint-Étienne, France.
  • Department of Laboratory Hemostasis, University Hospital of Saint-Étienne, Saint-Étienne, France.

Förderung

  • Société Française d’Anesthésie et de Réanimation

Zitieren

APA

Lanoiselée, J., Gibert, A., Gouin-Thibault, I., Mansour, A., Pontis, A., Morizot, C., Goset, M., Molliex, S., Morel, J., Noyel, P., Azarnoush, K., Petrosyan, A., Delavenne, X., Zufferey, P. J., & Ollier, E. (2026). Optimising protamine dosing for heparin reversal after cardiopulmonary bypass: a population pharmacokinetic–pharmacodynamic study. British Journal of Anaesthesia. https://doi.org/10.1016/j.bja.2025.11.057

Vancouver

Lanoiselée J, Gibert A, Gouin-Thibault I, Mansour A, Pontis A, Morizot C, et al. Optimising protamine dosing for heparin reversal after cardiopulmonary bypass: a population pharmacokinetic–pharmacodynamic study. British Journal of Anaesthesia. 2026. doi:10.1016/j.bja.2025.11.057

BibTeX
@article{Lanoisele2026,
  author = {Lanoiselée, Julien and Gibert, Audrick and Gouin-Thibault, Isabelle and Mansour, Alexandre and Pontis, Adeline and Morizot, Camille and Goset, Marie and Molliex, Serge and Morel, Jérôme and Noyel, Pauline and Azarnoush, Kasra and Petrosyan, Andranik and Delavenne, Xavier and Zufferey, Paul J and Ollier, Edouard},
  title = {Optimising protamine dosing for heparin reversal after cardiopulmonary bypass: a population pharmacokinetic–pharmacodynamic study},
  journal = {British Journal of Anaesthesia},
  year = {2026},
  doi = {10.1016/j.bja.2025.11.057}
}
Kostenlos starten →